(Reuters) - Drug developer Lpath Inc said its experimental drug to treat renal cell carcinoma, the most common form of kidney cancer, failed in a mid-stage trial.
Patients taking the drug, Asonep, did not show significant survival rates without the disease worsening.
Lpath shares were down 39 percent in after-market trading on Tuesday.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Joyjeet Das)
Patients taking the drug, Asonep, did not show significant survival rates without the disease worsening.
Lpath shares were down 39 percent in after-market trading on Tuesday.
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Joyjeet Das)
via Smart Health Shop Forum http://ift.tt/1CMMbK2
No comments:
Post a Comment